|Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model|
Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ...
Journal for immunotherapy of cancer 6 (1), 17, 2018
|Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data|
KM Hallow, PJ Greasley, G Helmlinger, L Chu, HJ Heerspink, DW Boulton
American Journal of Physiology-Renal Physiology 315 (5), F1295-F1306, 2018
|Modeling Na+-Ca2+ exchange in the heart: Allosteric activation, spatial localization, sparks and excitation-contraction coupling|
L Chu, JL Greenstein, RL Winslow
Journal of molecular and cellular cardiology 99, 174-187, 2016
|Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet|
G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ...
European Journal of Pharmaceutical Sciences 109, S39-S46, 2017
|Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development|
G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ...
CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019
|Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology|
K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger
Frontiers in Immunology 10, 924, 2019
|Na+ microdomains and sparks: Role in cardiac excitation-contraction coupling and arrhythmias in ankyrin-B deficiency|
L Chu, JL Greenstein, RL Winslow
Journal of Molecular and Cellular Cardiology 128, 145-157, 2019
|Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 …|
T Yakovleva, V Sokolov, L Chu, W Tang, PJ Greasley, H Peilot Sjögren, ...
Diabetes, Obesity and Metabolism 21 (12), 2684-2693, 2019
|Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling|
V Sokolov, T Yakovleva, L Chu, W Tang, PJ Greasley, S Johansson, ...
CPT: pharmacometrics & systems pharmacology 9 (4), 222-229, 2020
|Quantitative modeling as a systematic approach for drug combination evaluation in immuno-oncology (IO)|
G Helmlinger, Y Kosinsky, L Chu, K Peskov, V Voronova, A Borodovsky, ...
Cancer Research 78 (13 Supplement), 2098-2098, 2018
|Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis|
B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ...
OncoImmunology 9 (1), 1748982, 2020
|CONTRIBUTION AND REGULATION OF SGLT1 AND SGLT2 IN HEALTHY AND TYPE 2 DIABETES SUBJECTS: A DRUG-DISEASE MODELING STUDY.|
T Yakovleva, V Sokolov, L Chu, RC Penland, W Tang, PJ Greasley, ...
CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S51-S51, 2018
|Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors|
L Chu, RC Penland, G Helmlinger, DW Boulton
J. Pharmacokinet Pharmacodyn 44, S92, 2017
|Model-based meta-analysis of safety for immune checkpoint inhibitor combinations and monotherapy.|
K Abdallah, B Shulgin, K Peskov, Y Kosinsky, A Vergara-Silva, ...
Journal of Clinical Oncology 35 (7_suppl), 89-89, 2017
|USING A SYSTEMS PHARMACOLOGY MODEL TO INVESTIGATE POTASSIUM HOMEOSTASIS IN HEALTHY AND HYPERKALEMIC SUBJECTS.|
G Helmlinger, L Chu, S Aksenov, R Penland, M Nagard, D Boulton
CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S115-S115, 2020
|Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model|
K Yuri, L Chu, M Shah, K Vishwanathan, C Larsson, A Bloecher, B Willis, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
|Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach|
G Helmlinger, I Azarov, Y Kosinsky, V Voronova, L Chu, S Mosely, ...
Cancer Research 79 (13 Supplement), 1082-1082, 2019
|Mechanistic insights and dose optimization for AZD3458, a novel selective PI3Kg immuno-modulator, using a quantitative systems approach|
PM Gutierrez, Y Kosinsky, K Peskov, I Azarov, L Chu, V Voronova, ...
Cancer Research 79 (13 Supplement), 104-104, 2019
|Using Quantitative Systems Pharmacology modeling to predict response and resistance of immune checkpoint inhibitors (ICI) in murine syngeneic tumors|
I Azarov, Y Kosinsky, V Voronova, L Chu, SIS Sitnikova, S Dovedi, ...
Mathematical modelling in biomedicine, 13-14, 2019
|Comparison of different approaches to modeling early tumor size dynamics for accurate prediction of survival in non-small cell lung cancer (NSCLC) clinical trials|
Y Kosinsky, I Azarov, L Chu, G Helmlinger, K Peskov, S Aksenov
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S123-S123, 2018